RecruitingACTRN12613001304729

A multicentre, observational, prospective study of the current practice in major centres in Australia and New Zealand for achieving haemostasis in consecutive patients who present with significant haemorrhage, thromboembolism or urgent surgery whilst on new or established oral anticoagulants

Sponsor

ARES Collaborative

Enrollment

2,000 participants

Start Date

May 20, 2012

Study Type

Observational

Conditions

Significant haemorrhage Urgent surgery Thromboembolism

Summary

To document in major centres in Australia and New Zealand the current practice for achieving haemostasis in patients who present with significant haemorrhage or require anticoagulant reversal for urgent surgery and/or a procedure whilst on new (dabigatran, rivaroxaban, or apixaban) or established (warfarin) oral anticoagulants. In patients whilst on oral anticoagulants who present with embolism, determine the circumstances and level of anticoagulation at the time of presentation.

Eligibility

Sex: Both males and females

Plain Language Summary

Simplified for easier understanding

This observational study is documenting what happens in major hospitals across Australia and New Zealand when patients on blood-thinning medications (anticoagulants) experience serious bleeding or need urgent surgery. The study is not testing a new treatment — it is collecting information about current medical practice to help improve care in the future. You may be eligible if: - You have taken a blood-thinning medication (dabigatran, rivaroxaban, apixaban, or warfarin) within the past 7 days - You have experienced significant bleeding, a blood clot, or need the blood thinner reversed for urgent surgery or a procedure You may NOT be eligible if: - Your bleeding is minor and does not require hospital admission, blood tests, or a change in medication - You are unable to have tests to check for recurrence of a blood clot Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

This is an observational study to document in major centres in Australia and New Zealand the current practice for achieving haemostasis in patients who present with significant haemorrhage, thromboembolism or require anticoagulant reversal for urgent surgery and/or a procedure whilst on new (dabigatran, rivaroxaban, or apixaban) or established (warfarin) oral anticoagulants. The duration of the study is 42 months.